Gatralimab (GZ-402668) is a next-generation humanized anti-CD52 monoclonal antibody for which phase 1 clinical trial data indicate it successfully achieves the intended pharmacodynamic effect of lymphocyte depletion followed by subsequent repopulation, all with an acceptable safety profile, supporting its further investigation about relapsing-remitting multiple sclerosis (MS).
Purity:
95%
CAS Number:
[1826020-80-7]
Target:
NF-kappaB
* VAT and and shipping costs not included. Errors and price changes excepted
